Top Markets
Coin of the day
Tricida, Inc. Tricida, Inc.

Tricida, Inc.

TCDA
Rangering i aksjer #35026
Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the... Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the advancement and market introduction of veverimer (TRC101). This compound, an orally ingested, non-systemic polymer, has successfully concluded its Phase III clinical trials. Veverimer is designed to address metabolic acidosis in individuals suffering from chronic kidney disease by specifically targeting and eliminating excess acid within the gastrointestinal tract. The company was established in 2013 and is headquartered in South San Francisco, California.
Aksjekurs
$0.108
Sist synkronisert: 2023-01-23
Markedsverdi
$4.56M
Endring (1 dag)
-10.00%
Endring (1 år)
0.00%
Land
US
Handel Tricida, Inc. (TCDA)

Kategori

P/B-forhold for Tricida, Inc. (TCDA)
P/B-forhold per 2026 TTM: 0
Ifølge Tricida, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Tricida, Inc. fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.3419 -
US
6.2413 -
NL
- -
CH
- -
KR
3.4612 -
BE